Jazz Pharmaceuticals JAZZ Interest Expense
Interest Expense at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:InterestIncomeExpenseNonoperatingNet.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's interest expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's interest expense?
- Jazz Pharmaceuticals (JAZZ) reported interest expense of -$39.9M in Q1 2026.
- How has Jazz Pharmaceuticals's interest expense changed year-over-year?
- Jazz Pharmaceuticals's interest expense increased by 25.7% year-over-year, from -$53.7M to -$39.9M.
- What is the long-term trend for Jazz Pharmaceuticals's interest expense?
- Over 4 years (2021 to 2025), Jazz Pharmaceuticals's interest expense has grown at a 15.8% compound annual growth rate (CAGR), from $138.27M to $248.56M.
- What does interest expense mean?
- The cost of borrowing money.
- How do you interpret interest expense?
- Higher interest expense relative to operating income indicates increased financial risk and leverage.
- How does interest expense compare across companies?
- Standard expense item for all companies with debt.